Cyclophosphamide for the treatment of acute lymphoblastic leukemia: A protocol for systematic review.

Abstract

BACKGROUND:

Previous clinical trials have reported that cyclophosphamide can be used for the treatment of acute lymphoblastic leukemia (ALL). However, its efficacy is still unclear. In this systematic review study, we aim to evaluate its efficacy and safety for ALL.

METHODS:

The following 9 databases will be searched from their inception to the present: Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and Complementary Medicine Database (AMED), and four Chinese databases. The randomized controlled trials or case control studies of cyclophosphamide that assess the clinical efficacy and safety in patients with ALL are included. The methodological quality of all eligible included studies will be assessed by the Cochrane risk of bias tool.The primary outcome measurement will be all-cause mortality at the period of treatment and follow-up. The secondary outcome measurements will include the health-related quality of life (HRQL), postinduction complete remission (CR) rate, event-free survival (EFS), relapse rate, and adverse events. Two authors will independently select eligible studies, exact data, and assess the methodological quality of included studies. RevMan 5.3 software will be used to synthesize the data. Reporting bias will be evaluated by the funnel plots, Begg, and Egger tests.

RESULTS:

This systematic review will evaluate the clinical efficacy and safety of cyclophosphamide for ALL.

DISSEMINATION AND ETHICS:

The findings of this review will summarize the present evidence of cyclophosphamide for ALL, and may provide guidance for clinical practice of cyclophosphamide for ALL. Its results will be published through peer-reviewed journals. This study does not need ethic approval, because it will not involve the individual data.

SYSTEMATIC REVIEW REGISTRATION:

PROSPERO CRD42018119333.

• Authors: Yue-Rong Zhao, Hong-Mei Song, Lei Ni
• Journal: Medicine (Medicine (Baltimore)) Vol. 98 Issue 5 Pg. e14293 (Feb 2019) ISSN: 1536-5964 [Electronic] United States
• PMID: 30702599 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Antineoplastic Agents, Alkylating
• Cyclophosphamide

Topics

• Antineoplastic Agents, Alkylating (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Humans
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)